Publication:
Azacitidine versus decitabine in patients with refractory anemia with excess blast-results of multicenter study

dc.contributor.coauthorSalim, Ozan
dc.contributor.coauthorToptas, Tayfur
dc.contributor.coauthorAvsar, Esin
dc.contributor.coauthorYucel, Orhan Kemal
dc.contributor.coauthorGeduk, Ayfer
dc.contributor.coauthorMehtap, Ozgur
dc.contributor.coauthorTombak, Anil
dc.contributor.coauthorTiftik, Eyup Naci
dc.contributor.coauthorDeveci, Burak
dc.contributor.coauthorKurtoglu, Erdal
dc.contributor.coauthorKara, Osman
dc.contributor.coauthorAtagunduz, Isik Kaygusuz
dc.contributor.coauthorTuglular, Tulin Firatli
dc.contributor.coauthorUndar, Levent
dc.contributor.departmentSchool of Medicine
dc.contributor.departmentKUH (Koç University Hospital)
dc.contributor.kuauthorFerhanoğlu, Ahmet Burhan
dc.contributor.kuauthorÖztürk, Erman
dc.contributor.schoolcollegeinstituteSCHOOL OF MEDICINE
dc.contributor.schoolcollegeinstituteKUH (KOÇ UNIVERSITY HOSPITAL)
dc.date.accessioned2024-11-09T23:23:30Z
dc.date.issued2016
dc.description.abstractThe present study aimed to compare the efficacy and safety of azacitidine and decitabine in patients with myelodysplastic syndrome (MDS). A total of 88 patients diagnosed with refractory anemia with excess blast (RAEB) treated with azacitidine (n = 57) or decitabine (n = 31) were evaluated. Comparisons between azacitidine and decitabine groups were performed in the whole cohort, and in a 1:1 propensity score-matched cohort in order to reduce the simple selection bias. Patients who received azacitidine or decitabine had comparable overall response rates in both the unmatched (49.1% vs. 64.5%, p = 0.166) and the propensity-matched cohorts (52% vs. 68%, p = 0.248). The cumulative incidence of AML transformation at one year was comparable between azacitidine and decitabine in the unmatched (24.0% vs. 31.3%, p = 0.26) and in the propensity-matched cohorts (18.7% vs. 31.5%, p = 0.11). There was no difference in terms of transfusion requirement, febrile neutropenia episodes or the need for antifungal use during the treatment cycles in the propensity-matched cohort. The median overall survival was 20.4 months for azacitidine and 16.8 months for decitabine (p = 0.59). Finally, we found that at least a four-cycle treatment with any HMA was a favorable factor. In conclusion, both azacitidine and decitabine have similar efficacy and toxicity profiles in the treatment of MDS-RAEB.
dc.description.indexedbyScopus
dc.description.indexedbyPubMed
dc.description.openaccessYES
dc.description.publisherscopeInternational
dc.description.sponsoredbyTubitakEuN/A
dc.description.volume45
dc.identifier.doi10.1016/j.leukres.2016.04.003
dc.identifier.issn0145-2126
dc.identifier.quartileQ3
dc.identifier.scopus2-s2.0-84963808224
dc.identifier.urihttps://doi.org/10.1016/j.leukres.2016.04.003
dc.identifier.urihttps://hdl.handle.net/20.500.14288/11257
dc.keywordsAzacitidine
dc.keywordsComparison
dc.keywordsDecitabine
dc.keywordsMDS
dc.language.isoeng
dc.publisherElsevier
dc.relation.ispartofLeukemia Research
dc.subjectHematology
dc.subjectOncology
dc.subjectCancer research
dc.titleAzacitidine versus decitabine in patients with refractory anemia with excess blast-results of multicenter study
dc.typeJournal Article
dspace.entity.typePublication
local.contributor.kuauthorÖztürk, Erman
local.contributor.kuauthorFerhanoğlu, Ahmet Burhan
relation.isOrgUnitOfPublicationd02929e1-2a70-44f0-ae17-7819f587bedd
relation.isOrgUnitOfPublicationf91d21f0-6b13-46ce-939a-db68e4c8d2ab
relation.isOrgUnitOfPublication.latestForDiscoveryd02929e1-2a70-44f0-ae17-7819f587bedd
relation.isParentOrgUnitOfPublication17f2dc8e-6e54-4fa8-b5e0-d6415123a93e
relation.isParentOrgUnitOfPublication055775c9-9efe-43ec-814f-f6d771fa6dee
relation.isParentOrgUnitOfPublication.latestForDiscovery17f2dc8e-6e54-4fa8-b5e0-d6415123a93e

Files